{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T00:36:06Z","timestamp":1793925366191,"version":"4.8.0"},"reference-count":122,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archivos de Bronconeumolog\u00eda"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.arbres.2025.10.008","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T08:04:13Z","timestamp":1760429053000},"page":"766-782","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Update 2025 of the Spanish COPD Guidelines (GesEPOC): Pharmacological Treatment of Stable COPD"],"prefix":"10.1016","volume":"61","author":[{"given":"Marc","family":"Miravitlles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Calle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pere","family":"Almagro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9-Tom\u00e1s","family":"G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Antonio","family":"Trigueros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efra\u00edn","family":"S\u00e1nchez-Angarita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borja G.","family":"Cos\u00edo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciro","family":"Casanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"L\u00f3pez-Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Antonio","family":"Riesco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pere","family":"Simonet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Rigau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ainel","family":"Iskakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Pastor Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Sobradillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardino","family":"Alc\u00e1zar-Navarrete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00e9","family":"Garin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Jos\u00e9","family":"Soler-Catalu\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arbres.2025.10.008_bib0615","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.arbres.2012.04.001","article-title":"Spanish COPD guidelines (GesEPOC). Pharmacological treatment of stable COPD","volume":"48","author":"Miravitlles","year":"2012","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2025.10.008_bib0620","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2147\/COPD.S124482","article-title":"Clinical audit of COPD in outpatient respiratory clinics in Spain: the EPOCONSUL study","volume":"12","author":"Calle","year":"2017","journal-title":"Int J Chron Obstruct Pulm Dis"},{"key":"10.1016\/j.arbres.2025.10.008_bib0625","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.arbres.2023.02.004","article-title":"Variations in chronic obstructive pulmonary disease outpatient care in respiratory clinics: results from the 2021 EPOCONSUL audit","volume":"59","author":"Calle Rubio","year":"2023","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2025.10.008_bib0630","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.arbres.2012.12.001","article-title":"Calidad y fuerza: el sistema GRADE para la formulaci\u00f3n de recomendaciones en las gu\u00edas de pr\u00e1ctica cl\u00ednica","volume":"49","author":"Alonso-Coello","year":"2013","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2025.10.008_bib0635","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.arbres.2017.03.018","article-title":"Spanish COPD guidelines (GesEPOC) 2017. Pharmacological treatment of stable chronic obstructive pulmonary disease","volume":"53","author":"Miravitlles","year":"2017","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2025.10.008_bib0640","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.arbres.2021.03.026","article-title":"Updated Pharmacological treatment of stable COPD","volume":"58","author":"Miravitlles","year":"2022","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2025.10.008_bib0645","doi-asserted-by":"crossref","first-page":"T159","DOI":"10.1016\/j.arbres.2021.05.033","article-title":"Spanish COPD guidelines (GesEPOC) 2021 update. Diagnosis and treatment of COPD exacerbation syndrome","volume":"58","author":"Soler-Catalu\u00f1a","year":"2022","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2025.10.008_bib0650","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1378\/chest.06-1349","article-title":"Spirometric criteria for airway obstruction: use percentage of FEV1\/FVC ratio below the fifth percentile, not <70%","volume":"131","author":"Hansen","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.arbres.2025.10.008_bib0655","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1378\/chest.10-1721","article-title":"Overdiagnosing subjects with COPD using the 0.7 fixed ratio: correlation with a poor health-related quality of life","volume":"139","author":"Garc\u00eda-R\u00edo","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.arbres.2025.10.008_bib0660","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1136\/thoraxjnl-2019-213554","article-title":"Healthcare system encounters before COPD diagnosis: a registry-based longitudinal cohort study","volume":"75","author":"Johnson","year":"2020","journal-title":"Thorax"},{"key":"10.1016\/j.arbres.2025.10.008_bib0665","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.medcli.2011.06.022","article-title":"Validaci\u00f3n de la versi\u00f3n traducida del Chronic Obstructive Pulmonary Disease-Population Screener (COPD-PS). Su utilidad y la del FEV1\/FEV6 para el diagn\u00f3stico de enfermedad pulmonar obstructiva cr\u00f3nica","volume":"139","author":"Miravitlles","year":"2012","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.arbres.2025.10.008_bib0670","doi-asserted-by":"crossref","DOI":"10.1016\/j.arbres.2024.07.025","article-title":"Diagnostic accuracy of the combined modality of a questionnaire and a portable device for COPD case finding: experience with the PUMA questionnaire","author":"Montes de Oca","year":"2024","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2025.10.008_bib0675","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1378\/chest.127.5.1560","article-title":"FEV1\/FEV6 and FEV6 as an alternative for FEV1\/FVC and FVC in the spirometric detection of airway obstruction and restriction","volume":"127","author":"Vandevoorde","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.arbres.2025.10.008_bib0680","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.arbres.2010.04.008","article-title":"Validaci\u00f3n del dispositivo port\u00e1til COPD-6 para la detecci\u00f3n de patolog\u00edas obstructivas de la v\u00eda a\u00e9rea","volume":"46","author":"Represas","year":"2010","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2025.10.008_bib0685","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.arbres.2021.08.010","article-title":"Spanish COPD guidelines (GesEPOC 2021): non-pharmacological treatment update","volume":"58","author":"Cos\u00edo","year":"2022","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2025.10.008_bib0690","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.arbres.2021.08.002","article-title":"Spanish COPD guideline (GesEPOC) update: comorbidities self-management and palliative care","volume":"58","author":"Lopez-Campos","year":"2022","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2025.10.008_bib0695","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.arbres.2018.12.002","article-title":"Prognostic validation using GesEPOC 2017 severity criteria","volume":"55","author":"Cabrera L\u00f3pez","year":"2019","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2025.10.008_bib0700","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.arbres.2018.12.007","article-title":"Should lung function be included in the risk stratification of chronic obstructive pulmonary disease proposed by GesEPOC?","volume":"55","author":"Golpe","year":"2019","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2025.10.008_bib0705","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.arbres.2019.09.016","article-title":"Adjusting the level of intervention in patients with chronic obstructive pulmonary disease according to the risk stratification proposed by the Spanish COPD Guidelines (GesEPOC) version 2017","volume":"56","author":"Erro Iribarren","year":"2020","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2025.10.008_bib0710","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1164\/rccm.202008-3328PP","article-title":"From GOLD 0 to pre-COPD","volume":"203","author":"Han","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.arbres.2025.10.008_bib0715","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00334-2022","article-title":"Unravelling young COPD and pre-COPD in the general population","volume":"9","author":"Cosio","year":"2023","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.arbres.2025.10.008_bib0720","doi-asserted-by":"crossref","DOI":"10.1016\/j.arbres.2025.05.004","article-title":"Lung diffusing capacity improves the prognostic validity of the GOLD spirometric staging in COPD","author":"Casanova","year":"2025","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2025.10.008_bib0725","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.chest.2021.03.069","article-title":"Natural course of the diffusing capacity of the lungs for carbon monoxide in COPD: importance of sex","volume":"160","author":"Casanova","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.arbres.2025.10.008_bib0730","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1001\/jamainternmed.2015.2735","article-title":"Clinical and radiologic disease in smokers with normal spirometry","volume":"175","author":"Regan","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.arbres.2025.10.008_bib0735","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02214-2018","article-title":"Radiographic lung volumes predict progression to COPD in smokers with preserved spirometry in SPIROMICS","volume":"54","author":"Arjomandi","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2025.10.008_bib0740","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/resp.14223","article-title":"Chest CT-assessed comorbidities and all-cause mortality risk in COPD patients in the BODE cohort","volume":"27","author":"Ezponda","year":"2022","journal-title":"Respirology"},{"key":"10.1016\/j.arbres.2025.10.008_bib0745","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0034-2023","article-title":"The role of vaccination in COPD: influenza, SARS-CoV-2, pneumococcus, pertussis, RSV and varicella zoster virus","volume":"32","author":"Simon","year":"2023","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.arbres.2025.10.008_bib0750","doi-asserted-by":"crossref","DOI":"10.1016\/j.arbres.2025.06.005","article-title":"SEPAR recommendations on vaccination for chronic respiratory patients","author":"de Miguel-D\u00edez","year":"2025","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2025.10.008_bib0755","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.arbres.2022.11.005","article-title":"Challenges in the pharmacotherapy of COPD subtypes","volume":"59","author":"Polverino","year":"2023","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2025.10.008_bib0760","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001495","article-title":"Short-acting beta-2 agonists for stable chronic obstructive pulmonary disease","author":"Sestini","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.arbres.2025.10.008_bib0765","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1378\/chest.125.1.249","article-title":"The role of long-acting bronchodilators in the management of stable COPD","volume":"125","author":"Tashkin","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.arbres.2025.10.008_bib0770","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.amjmed.2017.12.018","article-title":"The role of fixed-dose dual bronchodilator therapy in treating COPD","volume":"131","author":"Anzueto","year":"2018","journal-title":"Am J Med"},{"key":"10.1016\/j.arbres.2025.10.008_bib0775","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1741-7015-7-2","article-title":"Inhaled drugs to reduce exacerbations in patients with chronic obstructive pulmonary disease: a network meta-analysis","volume":"7","author":"Puhan","year":"2009","journal-title":"BMC Med"},{"key":"10.1016\/j.arbres.2025.10.008_bib0780","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1056\/NEJMoa1008378","article-title":"Tiotropium versus salmeterol for the prevention of exacerbations of COPD","volume":"364","author":"Vogelmeier","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arbres.2025.10.008_bib0785","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S2213-2600(13)70158-9","article-title":"Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study","volume":"1","author":"Decramer","year":"2013","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.arbres.2025.10.008_bib0790","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.rmed.2016.01.001","article-title":"Magnitude of umeclidinium\/vilanterol lung function effect depends on monotherapy responses: results from two randomised controlled trials","volume":"112","author":"Donohue","year":"2016","journal-title":"Respir Med"},{"key":"10.1016\/j.arbres.2025.10.008_bib0795","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.chest.2016.02.646","article-title":"A systematic review with meta-analysis of dual bronchodilation with LAMA\/LABA for the treatment of stable COPD","volume":"149","author":"Calzetta","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.arbres.2025.10.008_bib0800","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1513\/AnnalsATS.201912-915OC","article-title":"Dual LABA\/LAMA therapy versus LABA or LAMA monotherapy for chronic obstructive pulmonary disease. A systematic review and meta-analysis in support of the American Thoracic Society Clinical Practice Guideline","volume":"17","author":"Mammen","year":"2020","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.arbres.2025.10.008_bib0805","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1186\/s12931-022-02268-3","article-title":"Exercise capacity and physical activity in COPD patients treated with a LAMA\/LABA combination: a systematic review and meta-analysis","volume":"23","author":"Miravitlles","year":"2022","journal-title":"Respir Res"},{"key":"10.1016\/j.arbres.2025.10.008_bib0810","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.arbres.2021.09.018","article-title":"The hidden and unchecked judgement calls when using exacerbation history for managing COPD","volume":"58","author":"Sadatsafavi","year":"2022","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2025.10.008_bib0815","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01921-2019","article-title":"The effect of exacerbation history on outcomes in the IMPACT trial","volume":"55","author":"Halpin","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2025.10.008_bib0820","doi-asserted-by":"crossref","DOI":"10.1177\/17534666231213715","article-title":"The future exacerbation and mortality of different inhalation therapies among patients with chronic obstructive pulmonary disease in various GOLD groups: a focus on the GOLD 2017 and GOLD 2023 reports","volume":"17","author":"Song","year":"2023","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.arbres.2025.10.008_bib0825","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.arbres.2017.04.002","article-title":"Consensus on the Asthma-COPD Overlap Syndrome (ACOS) between the Spanish COPD Guidelines (GesEPOC) and the Spanish Guidelines on the Management of Asthma (GEMA)","volume":"53","author":"Plaza","year":"2017","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2025.10.008_bib0830","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1080\/14737159.2024.2344777","article-title":"Clinical utilization of airway inflammatory biomarkers in the prediction and monitoring of clinical outcomes in patients with chronic obstructive pulmonary disease","volume":"24","author":"Yehia","year":"2024","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.arbres.2025.10.008_bib0835","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1164\/rccm.201408-1458OC","article-title":"Asthma-COPD overlap. Clinical relevance of genomic signatures of type 2 inflammation in chronic obstructive pulmonary disease","volume":"191","author":"Christenson","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.arbres.2025.10.008_bib0840","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1136\/thoraxjnl-2015-207021","article-title":"Blood eosinophils and inhaled corticosteroid\/long-acting \u03b2-2 agonist efficacy in COPD","volume":"71","author":"Pavord","year":"2016","journal-title":"Thorax"},{"key":"10.1016\/j.arbres.2025.10.008_bib0845","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.arbres.2021.11.006","article-title":"T2 biomarkers as predictors of exacerbations of chronic obstructive pulmonary disease","volume":"58","author":"Alc\u00e1zar-Navarrete","year":"2022","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2025.10.008_bib0850","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.arbres.2019.09.015","article-title":"Plasma eosinophil count and patient-centered events in chronic obstructive pulmonary disease in real-life clinical practice","volume":"56","author":"Golpe","year":"2020","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2025.10.008_bib0855","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01162-2017","article-title":"Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD","volume":"50","author":"Casanova","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2025.10.008_bib0860","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.arbres.2019.12.015","article-title":"Blood eosinophil counts and their variability and risk of exacerbations in COPD: a population-based study","volume":"57","author":"Miravitlles","year":"2021","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2025.10.008_bib0865","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12931-022-01965-3","article-title":"Determinants of blood eosinophil levels in the general population and patients with COPD: a population-based, epidemiological study","volume":"23","author":"Miravitlles","year":"2022","journal-title":"Respir Res"},{"key":"10.1016\/j.arbres.2025.10.008_bib0870","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S2213-2600(18)30368-0","article-title":"Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study","volume":"6","author":"Suissa","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.arbres.2025.10.008_bib0875","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1164\/rccm.201912-2384PP","article-title":"Blood eosinophil counts in clinical trials for chronic obstructive pulmonary disease","volume":"202","author":"Singh","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.arbres.2025.10.008_bib0880","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","article-title":"Once-daily single-inhaler triple versus dual therapy in patients with COPD","volume":"378","author":"Lipson","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arbres.2025.10.008_bib0885","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1916046","article-title":"Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD","volume":"383","author":"Rabe","year":"2020","journal-title":"N Engl J Med"},{"issue":"10048","key":"10.1016\/j.arbres.2025.10.008_bib0890","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S0140-6736(16)31354-X","article-title":"Single inhaler triple therapy versus inhaled corticosteroid plus long-acting \u03b22-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial","volume":"388","author":"Singh","year":"2016","journal-title":"Lancet"},{"issue":"10125","key":"10.1016\/j.arbres.2025.10.008_bib0895","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/S0140-6736(18)30206-X","article-title":"Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial","volume":"391","author":"Papi","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.arbres.2025.10.008_bib0900","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.arbres.2023.10.006","article-title":"Efficacy and safety of single-inhaler triple therapy containing dual bronchodilator with corticosteroids compared to monotherapy dual therapy, or open triple therapy in moderate\/severe COPD: a systematic literature review","volume":"60","author":"Riesco Miranda","year":"2024","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2025.10.008_bib0905","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.2147\/COPD.S310319","article-title":"Burden of disease among exacerbating patients with COPD treated with triple therapy in Spain","volume":"16","author":"Alc\u00e1zar-Navarrete","year":"2021","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.arbres.2025.10.008_bib0910","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.2147\/COPD.S378649","article-title":"Patients with chronic obstructive pulmonary disease and evidence of eosinophilic inflammation experience exacerbations despite receiving maximal inhaled maintenance therapy","volume":"17","author":"Chen","year":"2022","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.arbres.2025.10.008_bib0915","doi-asserted-by":"crossref","DOI":"10.1016\/j.opresp.2024.100306","article-title":"Biologics in COPD","volume":"6","author":"Kersul","year":"2024","journal-title":"Open Respir Arch"},{"key":"10.1016\/j.arbres.2025.10.008_bib0920","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S2213-2600(24)00409-0","article-title":"Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials","volume":"13","author":"Bhatt","year":"2025","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.arbres.2025.10.008_bib0925","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S2213-2600(13)70052-3","article-title":"Analysis of chronic obstructive pulmonar disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study","volume":"1","author":"Wedzicha","year":"2013","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.arbres.2025.10.008_bib0930","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S2213-2600(18)30102-4","article-title":"Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial","volume":"6","author":"Calverley","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.arbres.2025.10.008_bib0935","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1056\/NEJMoa1516385","article-title":"Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD","volume":"374","author":"Wedzicha","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arbres.2025.10.008_bib0940","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S2213-2600(19)30190-0","article-title":"Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial","volume":"7","author":"Pascoe","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.arbres.2025.10.008_bib0945","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1183\/13993003.01359-2015","article-title":"Treatable traits: toward precision medicine of chronic airway diseases","volume":"47","author":"Agusti","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2025.10.008_bib0950","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.2147\/COPD.S263430","article-title":"A proposed approach to chronic airway disease (CAD) using therapeutic goals and treatable traits: a look to the future","volume":"15","author":"P\u00e9rez de Llano","year":"2020","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.arbres.2025.10.008_bib0955","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00881-2020","article-title":"The right treatment for the right patient with COPD: lessons from the IMPACT trial","volume":"55","author":"Stolz","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2025.10.008_bib0960","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S2213-2600(16)30148-5","article-title":"Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis","volume":"4","author":"Pavord","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.arbres.2025.10.008_bib0965","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.2147\/COPD.S374670","article-title":"Benefits of budesonide\/glycopyrronium\/formoterol fumarate dihydrate on COPD exacerbations, lung function symptoms, and quality of life across blood eosinophil ranges: a post-hoc analysis of data from ETHOS","volume":"17","author":"Bafadhel","year":"2022","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.arbres.2025.10.008_bib0970","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00610-2017","article-title":"European Respiratory Society Statement: diagnosis and treatment of pulmonary disease in alpha-1 antitrypsin deficiency","volume":"50","author":"Miravitlles","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2025.10.008_bib0975","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.rmed.2004.10.009","article-title":"Efficacy of theophylline in people with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis","volume":"99","author":"Ram","year":"2005","journal-title":"Respir Med"},{"key":"10.1016\/j.arbres.2025.10.008_bib0980","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1378\/chest.119.6.1661","article-title":"Salmeterol plus theophylline combination therapy in the treatment of COPD","volume":"119","author":"ZuWallack","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.arbres.2025.10.008_bib0985","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/j.1440-1843.2006.00897.x","article-title":"Positive benefits of theophylline in a randomized, double-blind, parallel-group, placebo-controlled study of low-dose, slow-release theophylline in the treatment of COPD for 1 year","volume":"11","author":"Zhou","year":"2006","journal-title":"Respirology"},{"key":"10.1016\/j.arbres.2025.10.008_bib0990","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1001\/jama.2018.14432","article-title":"Effect of theophylline as adjunct to inhaled corticosteroids on exacerbations in patients with COPD: a randomized clinical trial","volume":"320","author":"Devereux","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.arbres.2025.10.008_bib0995","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.chest.2016.04.011","article-title":"Oral low-dose theophylline on top of inhaled fluticasone-salmeterol does not reduce exacerbations in patients with severe COPD: a pilot clinical trial","volume":"150","author":"Cos\u00edo","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.arbres.2025.10.008_bib1000","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.arbres.2023.03.016","article-title":"Estimated worldwide prevalence of the PI*ZZ alpha-1 antitrypsin genotype in subjects with chronic obstructive pulmonary disease","volume":"59","author":"Blanco","year":"2023","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2025.10.008_bib1005","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.arbres.2020.04.014","article-title":"Results of a diagnostic procedure based on multiplex technology on dried blood spots and buccal swabs for subjects with suspected alpha1 antitrypsin deficiency","volume":"57","author":"L\u00f3pez-Campos","year":"2021","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2025.10.008_bib1010","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.arbres.2020.02.003","article-title":"Spanish implementation of the new international alpha-1 antitrypsin deficiency international registry: the European Alpha-1 Research Collaboration (EARCO)","volume":"57","author":"Barrecheguren","year":"2021","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2025.10.008_bib1015","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1080\/15412555.2020.1795824","article-title":"The importance of reference centers and registries for rare diseases: the example of alpha-1 antitrypsin deficiency","volume":"17","author":"Miravitlles","year":"2020","journal-title":"COPD"},{"key":"10.1016\/j.arbres.2025.10.008_bib1020","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S0140-6736(15)60860-1","article-title":"Intravenous augmentation treatment and lung density in severe alpha-1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial","volume":"386","author":"Chapman","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.arbres.2025.10.008_bib1025","doi-asserted-by":"crossref","DOI":"10.1177\/17534666241271917","article-title":"Personalised indication of augmentation therapy for emphysema associated with severe alpha-1 antitrypsin deficiency: a case series","volume":"18","author":"Aljama","year":"2024","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.arbres.2025.10.008_bib1030","doi-asserted-by":"crossref","first-page":"6274","DOI":"10.21037\/jtd.2018.10.43","article-title":"Bronchoscopic treatment of emphysema: an update","volume":"10","author":"Poggi","year":"2018","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.arbres.2025.10.008_bib1035","doi-asserted-by":"crossref","DOI":"10.1016\/j.arbres.2025.03.015","article-title":"A systematic review and expert recommendation on the diagnosis of pulmonary hypertension associated with lung disease: a position paper of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR)","author":"Rodr\u00edguez-Chiarad\u00eda","year":"2025","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2025.10.008_bib1040","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.arbres.2025.10.008_bib1045","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01914-2018","article-title":"Pulmonary hypertension in chronic lung disease and hypoxia","volume":"53","author":"Nathan","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2025.10.008_bib1050","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1164\/rccm.201801-0095PP","article-title":"Pulmonary vascular involvement in chronic obstructive pulmonary disease. Is there a pulmonary vascular phenotype?","volume":"198","author":"Kovacs","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.arbres.2025.10.008_bib1055","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.arbres.2013.11.025","article-title":"Continuous home oxygen therapy","volume":"50","author":"Ortega Ruiz","year":"2014","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2025.10.008_bib1060","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.arbres.2022.09.014","article-title":"When and when not to prescribe home oxygen in COPD","volume":"59","author":"Lacasse","year":"2023","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2025.10.008_bib1065","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.opresp.2020.02.007","article-title":"Ventilaci\u00f3n mec\u00e1nica a domicilio Gu\u00eda SEPAR de las terapias domiciliarias","volume":"2","author":"Egea-Santaolalla","year":"2020","journal-title":"Open Respir Arch"},{"key":"10.1016\/j.arbres.2025.10.008_bib1070","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S2213-2600(14)70153-5","article-title":"Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: a prospective, multicentre, randomised, controlled clinical trial","volume":"2","author":"K\u00f6hnlein","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.arbres.2025.10.008_bib1075","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1513\/AnnalsATS.201512-800OC","article-title":"Persistent and newly developed chronic bronchitis are associated with worse outcomes in chronic obstructive pulmonary disease","volume":"13","author":"Kim","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.arbres.2025.10.008_bib1080","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/S0140-6736(08)60869-7","article-title":"Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomized placebo-controlled study","volume":"371","author":"Zheng","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.arbres.2025.10.008_bib1085","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1378\/chest.13-2784","article-title":"Benefits of high-dose N-acetylcysteine to exacerbation-prone patients with COPD","volume":"146","author":"Tse","year":"2014","journal-title":"Chest"},{"key":"10.1016\/j.arbres.2025.10.008_bib1090","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S2213-2600(13)70286-8","article-title":"Twice daily N-acetylcysteine 600mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial","volume":"2","author":"Zheng","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.arbres.2025.10.008_bib1095","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02265-2016","article-title":"Prevention of COPD exacerbations: an European Respiratory Society\/American Thoracic Society (ERS\/ATS) guideline","volume":"50","author":"Wedzicha","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2025.10.008_bib1100","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.arbres.2024.03.010","article-title":"N-acetylcysteine treatment in chronic obstructive pulmonary disease (COPD) and chronic bronchitis\/pre-COPD: distinct meta-analyses","volume":"60","author":"Papi","year":"2024","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2025.10.008_bib1105","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0140-6736(09)61252-6","article-title":"Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with long acting bronchodilators: two randomised clinical trials","volume":"374","author":"Fabbri","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.arbres.2025.10.008_bib1110","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1164\/rccm.201607-1349OC","article-title":"Effect of roflumilast and inhaled corticosteroid\/long-acting \u03b22-agonist on chronic obstructive pulmonary disease exacerbations (RE(2)SPOND). A randomized clinical trial","volume":"194","author":"Martinez","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.arbres.2025.10.008_bib1115","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.2147\/COPD.S132961","article-title":"Bronchiectasis in COPD patients. More than a comorbidity?","volume":"12","author":"Mart\u00ednez-Garc\u00eda","year":"2017","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.arbres.2025.10.008_bib1120","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1164\/rccm.201208-1518OC","article-title":"Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease","volume":"187","author":"Mart\u00ednez-Garc\u00eda","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.arbres.2025.10.008_bib1125","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.arbres.2024.04.003","article-title":"Clinical characteristics and outcomes of the phenotypes of COPD-bronchiectasis association","volume":"60","author":"Pan","year":"2024","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2025.10.008_bib1130","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.arbres.2017.07.016","article-title":"Spanish guidelines on the evaluation and diagnosis of bronchiectasis in adults","volume":"54","author":"Mart\u00ednez-Garc\u00eda","year":"2018","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2025.10.008_bib1135","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.arbres.2020.04.023","article-title":"Consensus document on the diagnosis and treatment of chronic bronchial infection in chronic obstructive pulmonary disease","volume":"56","author":"de la Rosa Carrillo","year":"2020","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2025.10.008_bib1140","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9061639","article-title":"Current challenges in chronic bronchial infection in patients with chronic obstructive pulmonary disease","volume":"9","author":"L\u00f3pez-Campos","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.arbres.2025.10.008_bib1145","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S2213-2600(14)70019-0","article-title":"Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial","volume":"2","author":"Uzun","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.arbres.2025.10.008_bib1150","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1056\/NEJMoa1104623","article-title":"Azithromycin for prevention of exacerbations of COPD","volume":"365","author":"Albert","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arbres.2025.10.008_bib1155","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.chest.2018.01.044","article-title":"Clinical and safety outcomes of long-term azithromycin therapy in severe COPD beyond the first year of treatment","volume":"153","author":"Pomares","year":"2018","journal-title":"Chest"},{"key":"10.1016\/j.arbres.2025.10.008_bib1160","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.2147\/COPD.S209513","article-title":"Nebulized colistin and continuous cyclic azithromycin in severe COPD patients with chronic bronchial infection due to pseudomonas aeruginosa: a retrospective cohort study","volume":"14","author":"Mont\u00f3n","year":"2019","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.arbres.2025.10.008_bib1165","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.arbres.2021.03.009","article-title":"Effectiveness and safety of inhaled antibiotics in patients with chronic obstructive pulmonary disease. A multicentre observational study","volume":"58","author":"De la Rosa Carrillo","year":"2022","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2025.10.008_bib1170","doi-asserted-by":"crossref","first-page":"8773","DOI":"10.1038\/s41598-025-91763-w","article-title":"Tolerance and effectiveness of inhaled antibiotics at standard or low doses in COPD patients with chronic Pseudomonas aeruginosa bronchial infection","volume":"15","author":"Costa","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.arbres.2025.10.008_bib1175","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.arbres.2020.06.003","article-title":"Changes in control status of COPD over time and their consequences: a prospective international study","volume":"57","author":"Miravitlles","year":"2021","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2025.10.008_bib1180","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.2147\/COPD.S178149","article-title":"Validation of clinical control in COPD as a new tool for optimizing treatment","volume":"13","author":"Soler-Catalu\u00f1a","year":"2018","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.arbres.2025.10.008_bib1185","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1111\/resp.13811","article-title":"Predictive value of control of COPD for risk of exacerbations: an international, prospective study","volume":"25","author":"Miravitlles","year":"2020","journal-title":"Respirology"},{"key":"10.1016\/j.arbres.2025.10.008_bib1190","doi-asserted-by":"crossref","first-page":"707","DOI":"10.3390\/jcm14030707","article-title":"Development and validation of a quantitative score for the criteria clinical control in stable COPD proposed in the Spanish COPD Guidelines (GesEPOC): results of the EPOCONSUL audit","volume":"14","author":"Calle Rubio","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.arbres.2025.10.008_bib1195","doi-asserted-by":"crossref","DOI":"10.1016\/j.arbres.2025.06.003","article-title":"Risk validation of a new quantitative score for clinical control of chronic obstructive pulmonary disease: the RADAR score","author":"Soler-Catalu\u00f1a","year":"2025","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2025.10.008_bib1200","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.rmed.2009.05.018","article-title":"Evaluation of withdrawal of maintenance tiotropium in COPD","volume":"103","author":"Adams","year":"2009","journal-title":"Respir Med"},{"key":"10.1016\/j.arbres.2025.10.008_bib1205","doi-asserted-by":"crossref","first-page":"00175","DOI":"10.1183\/23120541.00175-2018","article-title":"Tiotropium discontinuation in patients with early-stage COPD: a prospective observational cohort study","volume":"5","author":"Li","year":"2019","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.arbres.2025.10.008_bib1210","article-title":"Withdrawal of inhaled corticosteroids in chronic obstructive pulmonary disease: a European Respiratory Society Guideline","volume":"35","author":"Chalmers","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2025.10.008_bib1215","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0075-2021","article-title":"Systematic review on long-term adverse effects of inhaled corticosteroids in the treatment of COPD","volume":"30","author":"Miravitlles","year":"2021","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.arbres.2025.10.008_bib1220","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1093\/ageing\/afu115","article-title":"Prevalence of and interventions for sarcopenia in ageing adults: a systematic review Report of the International Sarcopenia Initiative (EWGSOP and IWGS)","volume":"43","author":"Cruz-Jentoft","year":"2014","journal-title":"Age Ageing"}],"container-title":["Archivos de Bronconeumolog\u00eda"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300289625003746?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300289625003746?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T15:01:56Z","timestamp":1764601316000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0300289625003746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":122,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0300289625003746"],"URL":"https:\/\/doi.org\/10.1016\/j.arbres.2025.10.008","relation":{},"ISSN":["0300-2896"],"issn-type":[{"value":"0300-2896","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update 2025 of the Spanish COPD Guidelines (GesEPOC): Pharmacological Treatment of Stable COPD","name":"articletitle","label":"Article Title"},{"value":"Archivos de Bronconeumolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arbres.2025.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 SEPAR. Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}